Heyuan Biological Technology (Tianjin) Co., Ltd. announced that it will receive CNY 58,000,000 in an equity round of funding from Zhongyuan Union Cell & Gene Engineering Corp., Ltd (SHSE:600645) on January 4, 2019. The investor will acquire stake in the transaction. The transaction has been approved by the 26th meeting of the 9th directorate of the investor. Post closing of the transaction, the investor will hold 21.642% stake in the company.